Drug,Chemical Structure,Adverse Effect / Toxicity,Species,Dose,Dose Type,Route,Source,Source Link,Year,no_stereoisomer
Abemaciclib,CCN1CCN(CC1)CC1=CC=C(NC2=NC=C(F)C(=N2)C2=CC3=C(N=C(C)N3C(C)C)C(F)=C2)N=C1,Cholecystitis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 208716/S-000 Part 09, page:25 PDF 678k",https://www.pharmapendium.com/browse/fda/Abemaciclib/a50315d3a726a8049e1d15f32cd253cf?reference=25,2017.0,CCN1CCN(CC1)CC1=CC=C(NC2=NC=C(F)C(=N2)C2=CC3=C(N=C(C)N3C(C)C)C(F)=C2)N=C1
Acalabrutinib,CC#CC(=O)N1CCC[C@H]1C1=NC(C2=CC=C(C=C2)C(=O)NC2=NC=CC=C2)=C2N1C=CN=C2N,Cholecystitis,Human,-1.4471580313422192,Repeated,Oral,"FDA approval package document: Approval Package 210259/S-000 Part 07, page:13 PDF 479k",https://www.pharmapendium.com/browse/fda/Acalabrutinib/790d7b2ca966a263cae6a013477587ca?reference=13,2017.0,CC#CC(=O)N1CCC[CH]1C1=NC(C2=CC=C(C=C2)C(=O)NC2=NC=CC=C2)=C2N1C=CN=C2N
Acitretin,COC1=CC(C)=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)=C1C,Cholecystitis,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 019821 Part 01, page:1 PDF 7773k",https://www.pharmapendium.com/browse/fda/Acitretin/1a0cb7a639fe6c5d73334f9d95bc1bc6?reference=1,1996.0,COC1=CC(C)=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)=C1C
Alosetron Hydrochloride,CN1C2=C(C(=O)N(CC2)CC2=C(C)NC=N2)C2=C1C=CC=C2,Cholecystitis,Human,-0.0,Repeated,Oral,"FDA approval package document: Approval Package 206647 Part 02, page:2 PDF 1085k",https://www.pharmapendium.com/browse/fda/Alosetron Hydrochloride/b844899fe2dcd0f784831fc7f492a893?reference=2,2016.0,CN1C2=C(C(=O)N(CC2)CC2=C(C)NC=N2)C2=C1C=CC=C2
Amiodarone Hydrochloride,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,Cholecystitis,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 018972/S-014 Part 17, page:29 PDF 4907k",https://www.pharmapendium.com/browse/fda/Amiodarone Hydrochloride/01d504d906d5404cd63b07c8e7335937?reference=29,1983.0,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1
Amphotericin B,[H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2,Cholecystitis,Human,-0.6989700043360189,Repeated,Intravenous,"FDA approval package document: Approval Package 050724 Part 04, page:6 PDF 4130k",https://www.pharmapendium.com/browse/fda/Amphotericin B/2d9ca1b6cf96fb8db3da224d7e9e499f?reference=6,1995.0,[H][C]12C[CH](O[CH]3O[CH](C)[CH](O)[CH](N)[CH]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[CH](C)[CH](O)[CH](C)[CH](C)OC(=O)C[CH](O)C[CH](O)CC[CH](O)[CH](O)C[CH](O)C[C](O)(C[CH](O)[CH]1C(O)=O)O2
Anastrozole,CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N,Cholecystitis,Human,-0.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020541/S-010 Part 02, page:14 PDF 2691k",https://www.pharmapendium.com/browse/fda/Anastrozole/6373bfaf67f083a9d0dc380d29635cfd?reference=14,2001.0,CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N
Anidulafungin,CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O,Cholecystitis,Human,-2.3010299956639813,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 021948/S-000; 021632/S-000 Part 02, page:65 PDF 3936k",https://www.pharmapendium.com/browse/fda/Anidulafungin/4e65267e8ff39cff9411a1cc5601321e?reference=65,2005.0,CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[CH]1C[CH](O)[CH](O)NC(=O)[CH]2[CH](O)[CH](C)CN2C(=O)[CH](NC(=O)[CH](NC(=O)[CH]2C[CH](O)CN2C(=O)[CH](NC1=O)[CH](C)O)[CH](O)[CH](O)C1=CC=C(O)C=C1)[CH](C)O
Aripiprazole,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl,Cholecystitis,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Label 021713/S-009; 021436/S-014, page:34 PDF 355k",https://www.pharmapendium.com/browse/fda/Aripiprazole/5fa5b3b87e61be15a4b85ecbb134a142?reference=34,2005.0,ClC1=CC=CC(N2CCN(CCCCOC3=CC=C4CCC(=O)NC4=C3)CC2)=C1Cl
Armodafinil,NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1,Cholecystitis,Human,-2.3979400086720375,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021875/S-000 Part 03, page:65 PDF 7194k",https://www.pharmapendium.com/browse/fda/Armodafinil/d678f4f141624a3f2cd5f7be0fc08f3a?reference=65,2007.0,NC(=O)C[S](=O)C(C1=CC=CC=C1)C1=CC=CC=C1
Axitinib,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=NC=CC=C3)=C2)C=CC=C1,Cholecystitis,Human,-1.3010299956639813,Repeated,Oral,"EMA approval document: ANNEX I, page:10 PDF 950k",https://www.pharmapendium.com/browse/ema/Axitinib/28a87ce85b0e5dfa8be0ab4dcd451624?reference=10,2021.0,CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=NC=CC=C3)=C2)C=CC=C1
Azilsartan Kamedoxomil,CCOC1=NC2=CC=CC(C(=O)OCC3=C(C)OC(=O)O3)=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC([O-])N1,Cholecystitis,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 200796/S-000 Part 04, page:36 PDF 6157k",https://www.pharmapendium.com/browse/fda/Azilsartan Kamedoxomil/795aa288e997610e4d3a2ddfe9669b1d?reference=36,2011.0,CCOC1=NC2=CC=CC(C(=O)OCC3=C(C)OC(=O)O3)=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC([O-])N1
Beclomethasone Dipropionate,[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C,Cholecystitis,Human,-2.505149978319906,Repeated,Intranasal,"FDA approval package document: Medical/Clinical Review 202813 Part 02, page:35 PDF 9850k",https://www.pharmapendium.com/browse/fda/Beclomethasone Dipropionate/62584b6541c546843ebd128590f529ca?reference=35,2012.0,[H][C]12C[CH](C)[C](OC(=O)CC)(C(=O)COC(=O)CC)[C]1(C)C[CH](O)[C]1(Cl)[C]2([H])CCC2=CC(=O)C=C[C]12C
Bempedoic Acid,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O,Cholecystitis,Human,-2.255272505103306,Repeated,Oral,"FDA approval package document: Approval Package 211616/S-000 Part 11, page:46 PDF 1857k",https://www.pharmapendium.com/browse/fda/Bempedoic Acid/2208c196ea39d0c896405f6c8e825e31?reference=46,2019.0,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O
Boceprevir,[H][C@]12CN([C@H](C(=O)NC(CC3CCC3)C(=O)C(N)=O)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C,Cholecystitis,Human,-3.380211241711606,Repeated,Oral,"EMA approval document: ANNEX I, page:13 PDF 428k",https://www.pharmapendium.com/browse/ema/Boceprevir/3eded3dcf36e4c3ebdde3f8dd5fdd6aa?reference=13,2012.0,[H][C]12CN([CH](C(=O)NC(CC3CCC3)C(=O)C(N)=O)[C]1([H])C2(C)C)C(=O)[CH](NC(=O)NC(C)(C)C)C(C)(C)C
Brexpiprazole,O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1,Cholecystitis,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 205422/S-000 Part 04, page:81 PDF 20059k",https://www.pharmapendium.com/browse/fda/Brexpiprazole/00ccb22ace460844be09f496a697ac0d?reference=81,2014.0,O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1
Buprenorphine,[H][C@@]1(C[C@]23CC[C@@]1(OC)[C@@H]1OC4=C(O)C=CC5=C4[C@]21CCN(CC1CC1)[C@@H]3C5)[C@](C)(O)C(C)(C)C,Cholecystitis,Human,-1.3010299956639813,Repeated,Skin,"FDA approval package document: Medical/Clinical Review 021306/S-000 Part 16, page:38 PDF 1329k",https://www.pharmapendium.com/browse/fda/Buprenorphine/6117e72337723eaeb98f11c892c7f083?reference=38,2010.0,[H][C]1(C[C]23CC[C]1(OC)[CH]1OC4=C(O)C=CC5=C4[C]21CCN(CC1CC1)[CH]3C5)[C](C)(O)C(C)(C)C
Buprenorphine Hydrochloride,[H][C@@]1(C[C@@]23CC[C@]1(OC)[C@@H]1OC4=C(O)C=CC5=C4[C@]21CCN(CC1CC1)[C@@H]3C5)[C@](C)(O)C(C)(C)C,Cholecystitis,Human,-1.0791812460476249,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 207932/S-000 Part 03, page:8 PDF 1378k",https://www.pharmapendium.com/browse/fda/Buprenorphine Hydrochloride/31408b2c410259c9ac8c038b8eee727f?reference=8,2015.0,[H][C]1(C[C]23CC[C]1(OC)[CH]1OC4=C(O)C=CC5=C4[C]21CCN(CC1CC1)[CH]3C5)[C](C)(O)C(C)(C)C
Cabotegravir Sodium,[H][C@@]12CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C([O-])=C3C(=O)N1[C@@H](C)CO2,Cholecystitis,Human,-2.6020599913279625,Repeated,Intramuscular,"FDA approval package document: Review 212887/S-000; 212888/S-000 Part 18, page:17 PDF 1560k",https://www.pharmapendium.com/browse/fda/Cabotegravir Sodium/be955c24495f457e89987c3a768ca01f?reference=17,2019.0,[H][C]12CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C([O-])=C3C(=O)N1[CH](C)CO2
Cefepime Hydrochloride,CO\N=C(C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)\C1=CSC(N)=N1,Cholecystitis,Human,-3.3010299956639813,Repeated,Parenteral,"FDA approval package document: Approval Package 050679 Part 10, page:83 PDF 9169k",https://www.pharmapendium.com/browse/fda/Cefepime Hydrochloride/e11b724b8378a80dcad097995138d99f?reference=83,1996.0,CO\N=C(C(=O)N[CH]1[CH]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)\C1=CSC(N)=N1
Cefpodoxime Proxetil,COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N\OC)\C1=CSC(N)=N1)C2=O)C(=O)OC(C)OC(=O)OC(C)C,Cholecystitis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 050674/S-012; 050675/S-015 Part 01, page:14 PDF 1326k",https://www.pharmapendium.com/browse/fda/Cefpodoxime Proxetil/31669ae540059b1b8a6f96df9ce6c3b6?reference=14,1998.0,COCC1=C(N2[CH](SC1)[CH](NC(=O)C(=N\OC)\C1=CSC(N)=N1)C2=O)C(=O)OC(C)OC(=O)OC(C)C
Ciclesonide,[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]1(C)[C@@]2([H])C[C@H]2O[C@H](O[C@@]12C(=O)COC(=O)C(C)C)C1CCCCC1,Cholecystitis,Human,-2.3010299956639813,Repeated,Intranasal,"FDA approval package document: Medical/Clinical Review 022004/S-000, page:144 PDF 14928k",https://www.pharmapendium.com/browse/fda/Ciclesonide/0c825edd11b33eaf4bf8ff60272ea8c1?reference=144,2006.0,[H][C]12CCC3=CC(=O)C=C[C]3(C)[C]1([H])[CH](O)C[C]1(C)[C]2([H])C[CH]2O[CH](O[C]12C(=O)COC(=O)C(C)C)C1CCCCC1
Ciprofloxacin Hydrochloride,OC(=O)C1=CN(C2CC2)C2=C(C=C(F)C(=C2)N2CCNCC2)C1=O,Cholecystitis,Human,-2.6020599913279625,Repeated,Intravenous,"FDA approval package document: Approval Package 019847/S-002, S-008, S-015; 019857/S-004, S-008, S-017; 019858/S-004, S-007, S-008, S-009, S-015 Part 08, page:12 PDF 662k",https://www.pharmapendium.com/browse/fda/Ciprofloxacin Hydrochloride/472b205393340faa0a095f341f9c1ca5?reference=12,1991.0,OC(=O)C1=CN(C2CC2)C2=C(C=C(F)C(=C2)N2CCNCC2)C1=O
Citalopram Hydrobromide,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,Cholecystitis,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Approval Package 020822/S-042; 021046/S-019 Part 02, page:25 PDF 436k",https://www.pharmapendium.com/browse/fda/Citalopram Hydrobromide/4b374a2e2e10917b9d0839e1502121b5?reference=25,2012.0,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Cladribine,NC1=NC(Cl)=NC2=C1N=CN2[C@@H]1C[C@H](O)[C@@H](CO)O1,Cholecystitis,Human,-1.1139433523068367,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022561/S-000 Part 11, page:18 PDF 23631k",https://www.pharmapendium.com/browse/fda/Cladribine/cdf7c590901bed412a0ba7bd776ef517?reference=18,2010.0,NC1=NC(Cl)=NC2=C1N=CN2[CH]1C[CH](O)[CH](CO)O1
Conivaptan Hydrochloride,CC1=NC2=C(N1)C1=CC=CC=C1N(CC2)C(=O)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=CC=C2)C=C1,Cholecystitis,Human,-1.9030899869919435,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 021697/S-000 Part 01, page:80 PDF 5759k",https://www.pharmapendium.com/browse/fda/Conivaptan Hydrochloride/d4c3ea267d1e8379dd3867ad0fc78825?reference=80,2005.0,CC1=NC2=C(N1)C1=CC=CC=C1N(CC2)C(=O)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=CC=C2)C=C1
Dasatinib,CC1=NC(=CC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=N1)N1CCN(CCO)CC1,Cholecystitis,Human,-2.146128035678238,Repeated,Oral,"EMA approval document: ANNEX I, page:14 PDF 1664k",https://www.pharmapendium.com/browse/ema/Dasatinib/77004e26e51c3fd64afb4e0b6a644257?reference=14,2020.0,CC1=NC(=CC(NC2=NC=C(S2)C(=O)NC2=C(Cl)C=CC=C2C)=N1)N1CCN(CCO)CC1
Dexlansoprazole,CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1,Cholecystitis,Human,-1.954242509439325,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022287/S-000 Part 01, page:87 PDF 8272k",https://www.pharmapendium.com/browse/fda/Dexlansoprazole/b4bdf5642030608f2528604c055c80d6?reference=87,2009.0,CC1=C(OCC(F)(F)F)C=CN=C1C[S](=O)C1=NC2=CC=CC=C2N1
Diclofenac Sodium,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,Cholecystitis,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 019201/S-001, S-002, S-003, S-005, S-007, S-009, S-010, S-013, S-014, S-015, S-019, S-021 Part 06, page:3 PDF 5413k",https://www.pharmapendium.com/browse/fda/Diclofenac Sodium/c56ad2267611ad95c9ab82329518aad8?reference=3,1988.0,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
Didanosine,OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1N=CNC2=O,Cholecystitis,Human,-2.8750612633917,Repeated,Oral,"FDA approval package document: Approval Package 020154/S-009, S-011, S-020; 020155/S-007, S-016; 020156/S-007, S-016 Part 10, page:1 PDF 7736k",https://www.pharmapendium.com/browse/fda/Didanosine/92b2914714832f57db669f7ea5f017e2?reference=1,1991.0,OC[CH]1CC[CH](O1)N1C=NC2=C1N=CNC2=O
Donepezil Hydrochloride,COC1=C(OC)C=C2C(=O)C(CC3CCN(CC3)CC3=CC=CC=C3)CC2=C1,Cholecystitis,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 020690/S-011, page:5 PDF 1420k",https://www.pharmapendium.com/browse/fda/Donepezil Hydrochloride/ef2ae315038913ac33f9a72dc8b8e642?reference=5,2003.0,COC1=C(OC)C=C2C(=O)C(CC3CCN(CC3)CC3=CC=CC=C3)CC2=C1
Doravirine,CN1C(=O)NN=C1CN1C=CC(=C(OC2=CC(=CC(Cl)=C2)C#N)C1=O)C(F)(F)F,Cholecystitis,Human,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 210806/S-000 Part 06, page:60 PDF 11051k",https://www.pharmapendium.com/browse/fda/Doravirine/7babb97ed6a4ea205e52af3956344af6?reference=60,2018.0,CN1C(=O)NN=C1CN1C=CC(=C(OC2=CC(=CC(Cl)=C2)C#N)C1=O)C(F)(F)F
Doripenem,[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,Cholecystitis,Human,-0.9030899869919435,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 022106/S-000 Part 01, page:80 PDF 5816k",https://www.pharmapendium.com/browse/fda/Doripenem/d6bc063da6f57e9b9976728e8da0c7da?reference=80,2007.0,[H][C]12[CH](C)C(S[CH]3CN[CH](CNS(N)(=O)=O)C3)=C(N1C(=O)[C]2([H])[CH](C)O)C(O)=O
Eletriptan Hydrobromide,CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2,Cholecystitis,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021016/S-000 Part 04, page:42 PDF 1803k",https://www.pharmapendium.com/browse/fda/Eletriptan Hydrobromide/a93ca5efe23502ee7d9857dc8627193d?reference=42,2002.0,CN1CCC[CH]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2
Eplerenone,[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC,Cholecystitis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021437/S-000 Part 03, page:26 PDF 1378k",https://www.pharmapendium.com/browse/fda/Eplerenone/1cbab8e2e3f0797546ca8e9b1e0ff09b?reference=26,2002.0,[H][C]12CC[C]3(CCC(=O)O3)[C]1(C)C[CH]1O[C]11[C]2([H])[CH](CC2=CC(=O)CC[C]12C)C(=O)OC
Ertapenem Sodium,[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)NC3=CC(=CC=C3)C([O-])=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,Cholecystitis,Human,-3.0,Repeated,Intravenous,"EMA approval document: ANNEX I, page:7 PDF 281k",https://www.pharmapendium.com/browse/ema/Ertapenem Sodium/a6339cdc463b911132be37d8f0e36807?reference=7,2021.0,[H][C]12[CH](C)C(S[CH]3CN[CH](C3)C(=O)NC3=CC(=CC=C3)C([O-])=O)=C(N1C(=O)[C]2([H])[CH](C)O)C(O)=O
Estradiol Hemihydrate,[H][C@@]12CCC3=C(C=CC(O)=C3)C1CC[C@]1(C)[C@H](O)CCC21,Cholecystitis,Human,-4.681241237375588,Repeated,Skin,"FDA approval package document: Medical/Clinical Review 021371/S-000 Part 02, page:7 PDF 1114k",https://www.pharmapendium.com/browse/fda/Estradiol Hemihydrate/abf636236566af101c3e7668ceec2c72?reference=7,2002.0,[H][C]12CCC3=C(C=CC(O)=C3)C1CC[C]1(C)[CH](O)CCC21
Etodolac,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(O)=O,Cholecystitis,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 018922/S-007, S-008, S-013, S-014, S-015 Part 08, page:1 PDF 3345k",https://www.pharmapendium.com/browse/fda/Etodolac/d2333e37ec6437697ae86e18109bd36f?reference=1,1991.0,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(O)=O
Etonogestrel,[H][C@]12CCC(=O)C=C1CC[C@@]1([H])[C@]3([H])CC[C@@](O)(C#C)[C@@]3(CC)CC(=C)[C@]21[H],Cholecystitis,Human,-1.8325089127062364,Repeated,Implant,"FDA approval package document: Medical/Clinical Review 021529/S-000 Part 02, page:56 PDF 6598k",https://www.pharmapendium.com/browse/fda/Etonogestrel/bd73bf35b350db4f96079001c70b857a?reference=56,2006.0,[H][C]12CCC(=O)C=C1CC[C]1([H])[C]3([H])CC[C](O)(C#C)[C]3(CC)CC(=C)[C]21[H]
Everolimus,CO[C@@H]1C[C@@H](CC[C@H]1OCCO)C[C@@H](C)[C@@H]1CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1)OC,Cholecystitis,Human,-1.0,Repeated,Oral,"EMA approval document: Assessment Report EMA/390543/2016; EMEA/H/C/001038/II/0048, page:61 PDF 3428k",https://www.pharmapendium.com/browse/ema/Everolimus/7710b8aaa5e1c8c75df7cacf7c3d859c?reference=61,2016.0,CO[CH]1C[CH](CC[CH]1OCCO)C[CH](C)[CH]1CC(=O)[CH](C)\C=C(C)\[CH](O)[CH](OC)C(=O)[CH](C)C[CH](C)\C=C\C=C\C=C(C)\[CH](C[CH]2CC[CH](C)[C](O)(O2)C(=O)C(=O)N2CCCC[CH]2C(=O)O1)OC
Exemestane,[H][C@@]12CC(=C)C3=CC(=O)C=C[C@]3(C)[C@@]1([H])CC[C@]1(C)C(=O)CC[C@@]21[H],Cholecystitis,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020753/S-000 Part 02, page:19 PDF 1232k",https://www.pharmapendium.com/browse/fda/Exemestane/8db2b86d2b799cb1675f25ac0d8ba7ae?reference=19,1999.0,[H][C]12CC(=C)C3=CC(=O)C=C[C]3(C)[C]1([H])CC[C]1(C)C(=O)CC[C]21[H]
Ezetimibe,O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1,Cholecystitis,Human,-1.0,Repeated,Oral,"FDA approval package document: Label 021445/S-013, page:14 PDF 429k",https://www.pharmapendium.com/browse/fda/Ezetimibe/14e08036769a34cbfa47a8d80e04d720?reference=14,2006.0,O[CH](CC[CH]1[CH](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1
Ezogabine,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1,Cholecystitis,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022345/S-000 Part 01, page:77 PDF 772k",https://www.pharmapendium.com/browse/fda/Ezogabine/9413bf7d0c5e49a43f0fc5f8fd7d508b?reference=77,2011.0,CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1
Febuxostat,CC(C)COC1=CC=C(C=C1C#N)C1=NC(C)=C(S1)C(O)=O,Cholecystitis,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Label 021856/S-000, page:4 PDF 329k",https://www.pharmapendium.com/browse/fda/Febuxostat/cb2dd76be1473b65cae6848e33169719?reference=4,2009.0,CC(C)COC1=CC=C(C=C1C#N)C1=NC(C)=C(S1)C(O)=O
Felodipine,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC,Cholecystitis,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 019834/S-001, S-002, S-009 Part 08, page:37 PDF 6712k",https://www.pharmapendium.com/browse/fda/Felodipine/b6a4c7f7a92ebdea56e46db941d2f4b6?reference=37,1997.0,CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC
Fenofibrate,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1,Cholecystitis,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 019304 Part 03, page:47 PDF 7698k",https://www.pharmapendium.com/browse/fda/Fenofibrate/7c467e5c47086a300ef271deadab1c7d?reference=47,1993.0,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
Fexofenadine Hydrochloride,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,Cholecystitis,Human,-2.5563025007672873,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 201373/S-000 Part 06, page:2 PDF 321k",https://www.pharmapendium.com/browse/fda/Fexofenadine Hydrochloride/2e7486baa94f570d20d465293556c8a8?reference=2,2010.0,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
Fluoxetine Hydrochloride,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,Cholecystitis,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 020187 Part 04, page:19 PDF 10277k",https://www.pharmapendium.com/browse/fda/Fluoxetine Hydrochloride/29c51200452a4b8d4f8516fb73f5d045?reference=19,1994.0,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Flurbiprofen,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1,Cholecystitis,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Label 018766/S-013, page:11 PDF 339k",https://www.pharmapendium.com/browse/fda/Flurbiprofen/42077615ee502ab6ea0ace4341e5e783?reference=11,2006.0,CC(C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1
Fluticasone Propionate,[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C,Cholecystitis,Human,-3.0,Repeated,Inhalation,"FDA approval package document: Medical/Clinical Review 208798/S-000, page:136 PDF 18534k",https://www.pharmapendium.com/browse/fda/Fluticasone Propionate/e0d19891639bb6dbe0eb33be98b0b680?reference=136,2016.0,[H][C]12C[CH](C)[C](OC(=O)CC)(C(=O)SCF)[C]1(C)C[CH](O)[C]1(F)[C]2([H])C[CH](F)C2=CC(=O)C=C[C]12C
Hydromorphone Hydrochloride,[H][C@]12CCC(=O)[C@@H]3OC4=C5C(C[C@H]1N(C)CC[C@@]235)=CC=C4O,Cholecystitis,Human,-1.380211241711606,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021044/S-000, page:44 PDF 8823k",https://www.pharmapendium.com/browse/fda/Hydromorphone Hydrochloride/0bbc81d84ba86839664ce5bbbb449ec6?reference=44,2004.0,[H][C]12CCC(=O)[CH]3OC4=C5C(C[CH]1N(C)CC[C]235)=CC=C4O
Ibrutinib,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[C@@H]1CCCN(C1)C(=O)C=C,Cholecystitis,Human,-2.6232492903979003,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/473724/2015; EMEA/H/C/003791/II/0001, page:41 PDF 2703k",https://www.pharmapendium.com/browse/ema/Ibrutinib/3509c053a50f597a98dadfa00620acfc?reference=41,2015.0,NC1=C2C(=NC=N1)N(N=C2C1=CC=C(OC2=CC=CC=C2)C=C1)[CH]1CCCN(C1)C(=O)C=C
Ipratropium Bromide,CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1,Cholecystitis,Human,-3.1760912590556813,Repeated,Inhalation,"FDA approval package document: Approval Package 020228 Part 02, page:52 PDF 7029k",https://www.pharmapendium.com/browse/fda/Ipratropium Bromide/afca368ceebd4571754c70ed724cc024?reference=52,1992.0,CC(C)[N+]1(C)[CH]2CC[CH]1C[CH](C2)OC(=O)C(CO)C1=CC=CC=C1
Isosorbide Mononitrate,[H][C@]12OC[C@@H](ON(=O)=O)[C@@]1([H])OC[C@@H]2O,Cholecystitis,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 020225 Part 08, page:29 PDF 6332k",https://www.pharmapendium.com/browse/fda/Isosorbide Mononitrate/b197ad732ffa89a36ae5a900f7a1666c?reference=29,1993.0,[H][C]12OC[CH](ON(=O)=O)[C]1([H])OC[CH]2O
Lasofoxifene,OC1=CC=C2[C@H]([C@H](CCC2=C1)C1=CC=CC=C1)C1=CC=C(OCCN2CCCC2)C=C1,Cholecystitis,Human,-0.6989700043360189,Repeated,Oral,"EMA approval document: ANNEX I, page:7 PDF 474k",https://www.pharmapendium.com/browse/ema/Lasofoxifene/4a30d26487d86d298e55209f18660544?reference=7,2013.0,OC1=CC=C2[CH]([CH](CCC2=C1)C1=CC=CC=C1)C1=CC=C(OCCN2CCCC2)C=C1
Lesinurad,OC(=O)CSC1=NN=C(Br)N1C1=C2C=CC=CC2=C(C=C1)C1CC1,Cholecystitis,Human,-2.6020599913279625,Repeated,Oral,"EMA approval document: Assessment Report EMA/6459/2016; EMEA/H/C/003932/0000, page:110 PDF 5667k",https://www.pharmapendium.com/browse/ema/Lesinurad/d22d8c9f5d65c0aae620ada4cabc6eaa?reference=110,2015.0,OC(=O)CSC1=NN=C(Br)N1C1=C2C=CC=CC2=C(C=C1)C1CC1
Levocetirizine Dihydrochloride,OC(=O)COCCN1CCN(CC1)[C@H](C1=CC=CC=C1)C1=CC=C(Cl)C=C1,Cholecystitis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 209089/S-000 Part 04, page:22 PDF 387k",https://www.pharmapendium.com/browse/fda/Levocetirizine Dihydrochloride/d25c7d6c837742cdf580740c5427ea3d?reference=22,2016.0,OC(=O)COCCN1CCN(CC1)[CH](C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Levofloxacin,C[C@H]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O,Cholecystitis,Human,-2.3979400086720375,Repeated,Oral,"FDA approval package document: Approval Package 020634/S-000 Part 02, page:75 PDF 5144k",https://www.pharmapendium.com/browse/fda/Levofloxacin/73bdc88dc9e25c891cee022f7c463c82?reference=75,1996.0,C[CH]1COC2=C(N3CCN(C)CC3)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
Linaclotide,[H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@]3([H])CSSC[C@]([H])(NC(=O)[C@H](C)NC(=O)[C@]4([H])CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@]([H])(CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O,Cholecystitis,Human,-2.462397997898956,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202811/S-000 Part 14, page:13 PDF 687k",https://www.pharmapendium.com/browse/fda/Linaclotide/566bb35f6fb96f669e455348686f9537?reference=13,2012.0,[H][C]1(CSSC[C]2([H])NC(=O)[CH](CC3=CC=C(O)C=C3)NC(=O)[CH](CCC(O)=O)NC(=O)[C]3([H])CSSC[C]([H])(NC(=O)[CH](C)NC(=O)[C]4([H])CCCN4C(=O)[CH](CC(N)=O)NC(=O)[C]([H])(CSSC[CH](N)C(=O)N3)NC2=O)C(=O)N[C]([H])([CH](C)O)C(=O)NCC(=O)N1)C(=O)N[CH](CC1=CC=C(O)C=C1)C(O)=O
Liraglutide,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O,Cholecystitis,Human,-0.47712125471966244,Repeated,Subcutaneous,"FDA approval package document: Medical/Clinical Review 206321/S-000 Part 05, page:16 PDF 1019k",https://www.pharmapendium.com/browse/fda/Liraglutide/32d96e2cdb895f3bc12e2d8ac2b8f79e?reference=16,2014.0,CCCCCCCCCCCCCCCC(=O)N[CH](CCC(=O)NCCCC[CH](NC(=O)[CH](C)NC(=O)[CH](C)NC(=O)[CH](CCC(N)=O)NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](CC(C)C)NC(=O)[CH](CC1=CC=C(O)C=C1)NC(=O)[CH](CO)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC(O)=O)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC1=CC=CC=C1)NC(=O)[CH](NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](C)NC(=O)[CH](N)CC1=CN=CN1)[CH](C)O)[CH](C)O)C(C)C)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC1=CC=CC=C1)C(=O)N[CH]([CH](C)CC)C(=O)N[CH](C)C(=O)N[CH](CC1=CNC2=C1C=CC=C2)C(=O)N[CH](CC(C)C)C(=O)N[CH](C(C)C)C(=O)N[CH](CCCNC(N)=N)C(=O)NCC(=O)N[CH](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O
Lorcaserin Hydrochloride,C[C@H]1CNCCC2=CC=C(Cl)C=C12,Cholecystitis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022529/S-000 Part 09, page:11 PDF 2134k",https://www.pharmapendium.com/browse/fda/Lorcaserin Hydrochloride/290b233d73c8c3628efb1f5e7797d526?reference=11,2012.0,C[CH]1CNCCC2=CC=C(Cl)C=C12
Lorlatinib,C[C@H]1OC2=CC(=CN=C2N)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=C1C=C(F)C=C2,Cholecystitis,Human,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 210868/S-000 Part 09, page:57 PDF 1228k",https://www.pharmapendium.com/browse/fda/Lorlatinib/bd3ecb44dfc93ea65ade6b9e1d3ea355?reference=57,2018.0,C[CH]1OC2=CC(=CN=C2N)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=C1C=C(F)C=C2
Losartan Potassium,CCCCC1=NC(Cl)=C(C[O-])N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1,Cholecystitis,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020386/S-032 Part 02, page:47 PDF 1981k",https://www.pharmapendium.com/browse/fda/Losartan Potassium/438edb75f70f0b616380d7fde1ebcfa7?reference=47,2003.0,CCCCC1=NC(Cl)=C(C[O-])N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1
Lovastatin,[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC,Cholecystitis,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021316/S-000 Part 03, page:17 PDF 1478k",https://www.pharmapendium.com/browse/fda/Lovastatin/446165c8381ec6a613f35f2d993cc2ee?reference=17,2001.0,[H][C]12[CH](C[CH](C)C=C1C=C[CH](C)[CH]2CC[CH]1C[CH](O)CC(=O)O1)OC(=O)[CH](C)CC
Lubiprostone,[H][C@@]12CC(=O)[C@H](CCCCCCC(O)=O)[C@@]1([H])CC[C@@](O)(O2)C(F)(F)CCCC,Cholecystitis,Human,-0.9030899869919435,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021908/S-005, page:188 PDF 1936k",https://www.pharmapendium.com/browse/fda/Lubiprostone/aa91b24e7d450d9bfbc5df5035022691?reference=188,2010.0,[H][C]12CC(=O)[CH](CCCCCCC(O)=O)[C]1([H])CC[C](O)(O2)C(F)(F)CCCC
Mannitol,OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,Cholecystitis,Human,-2.9030899869919438,Repeated,Inhalation,"EMA approval document: Assessment Report EMA/CHMP/121817/2012, page:72 PDF 3591k",https://www.pharmapendium.com/browse/ema/Mannitol/92e8f2a00e99749b6cd00ba210c5c345?reference=72,2012.0,OC[CH](O)[CH](O)[CH](O)[CH](O)CO
Memantine Hydrochloride,[H][C@]12C[C@]3(C)C[C@](C)(C1)C[C@](N)(C2)C3,Cholecystitis,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021487/S-000 Part 04, page:40 PDF 1517k",https://www.pharmapendium.com/browse/fda/Memantine Hydrochloride/232901fe8089434495f89a3a69af53b3?reference=40,2003.0,[H][C]12C[C]3(C)C[C](C)(C1)C[C](N)(C2)C3
Mesalamine,NC1=CC(C(O)=O)=C(O)C=C1,Cholecystitis,Human,-3.9030899869919438,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021830/S-000 Part 01, page:78 PDF 6404k",https://www.pharmapendium.com/browse/fda/Mesalamine/e5ad55f280218bced0f82dd9483093bd?reference=78,2005.0,NC1=CC(C(O)=O)=C(O)C=C1
Metformin Hydrochloride,CN(C)C(=N)NC(N)=N,Cholecystitis,Human,-2.929418925714293,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020357 Part 03, page:6 PDF 1951k",https://www.pharmapendium.com/browse/fda/Metformin Hydrochloride/031d8bc21f6a622b853c27a3ef611e56?reference=6,,CN(C)C(=N)NC(N)=N
Micafungin Sodium,[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@]1([H])[C@@H](O)[C@@H](C)CN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[C@H](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O,Cholecystitis,Human,-2.1760912590556813,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 021754/S-000 Part 03, page:60 PDF 7132k",https://www.pharmapendium.com/browse/fda/Micafungin Sodium/0e7d32ac0bd233b9c781a736663a1981?reference=60,2005.0,[H][C]12C[CH](O)CN1C(=O)[CH](NC(=O)[CH](C[CH](O)[CH](O)NC(=O)[C]1([H])[CH](O)[CH](C)CN1C(=O)[CH](NC(=O)[CH](NC2=O)[CH](O)[CH](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[CH](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[CH](C)O
Mirtazapine,CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1,Cholecystitis,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020415 Part 03, page:45 PDF 1638k",https://www.pharmapendium.com/browse/fda/Mirtazapine/3ef88a665b5053f6fef17ab0f68687f9?reference=45,1995.0,CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1
Nabumetone,COC1=CC2=CC=C(CCC(C)=O)C=C2C=C1,Cholecystitis,Human,-3.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 019583/S-011 Part 04, page:95 PDF 5905k",https://www.pharmapendium.com/browse/fda/Nabumetone/1535f4946aea8632b96024e6dff7271f?reference=95,1995.0,COC1=CC2=CC=C(CCC(C)=O)C=C2C=C1
Naproxen Sodium,COC1=CC2=CC=C(C=C2C=C1)[C@H](C)C([O-])=O,Cholecystitis,Human,-3.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 020353 Part 01, page:6 PDF 659k",https://www.pharmapendium.com/browse/fda/Naproxen Sodium/92cbed8636118d690713ebb53d4409fc?reference=6,1996.0,COC1=CC2=CC=C(C=C2C=C1)[CH](C)C([O-])=O
Nebivolol Hydrochloride,[H][C@@]1(CCC2=CC(F)=CC=C2O1)[C@H](O)CNC[C@@H](O)[C@]1([H])CCC2=CC(F)=CC=C2O1,Cholecystitis,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021742/S-000 Part 07, page:44 PDF 5831k",https://www.pharmapendium.com/browse/fda/Nebivolol Hydrochloride/c22a1b61a9df4fdde7d3660c5a0ba709?reference=44,2007.0,[H][C]1(CCC2=CC(F)=CC=C2O1)[CH](O)CNC[CH](O)[C]1([H])CCC2=CC(F)=CC=C2O1
Nizatidine,CN\C(NCCSCC1=CSC(CN(C)C)=N1)=C\N(=O)=O,Cholecystitis,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 019508/S-012, S-016, S-012, S-013 Part 04, page:60 PDF 7658k",https://www.pharmapendium.com/browse/fda/Nizatidine/ed06d41b24ddb853e0691a6106b8e09e?reference=60,1991.0,CN\C(NCCSCC1=CSC(CN(C)C)=N1)=C\N(=O)=O
Obeticholic Acid,[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)[C@H](CC)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O,Cholecystitis,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 207999/S-000 Part 04, page:70 PDF 18785k",https://www.pharmapendium.com/browse/fda/Obeticholic Acid/fd9575acfa8e5dadbfa0aa39e5adfd26?reference=70,2016.0,[H][C]1(CC[C]2([H])[C]3([H])[CH](O)[CH](CC)[C]4([H])C[CH](O)CC[C]4(C)[C]3([H])CC[C]12C)[CH](C)CCC(O)=O
Olaparib,FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1,Cholecystitis,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 208558/S-000 Part 07, page:16 PDF 600k",https://www.pharmapendium.com/browse/fda/Olaparib/71eb8ad537ab4f6d59011e4d7b5329c7?reference=16,2017.0,FC1=CC=C(CC2=NNC(=O)C3=CC=CC=C23)C=C1C(=O)N1CCN(CC1)C(=O)C1CC1
Orlistat,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,Cholecystitis,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Approval Package 020766/S-018, page:58 PDF 7518k",https://www.pharmapendium.com/browse/fda/Orlistat/6b331278d6313ec2801283025e1a83e1?reference=58,2003.0,CCCCCCCCCCC[CH](C[CH]1OC(=O)[CH]1CCCCCC)OC(=O)[CH](CC(C)C)NC=O
Ospemifene,OCCOC1=CC=C(C=C1)C(\C1=CC=CC=C1)=C(\CCCl)C1=CC=CC=C1,Cholecystitis,Human,-1.954242509439325,Repeated,Oral,"EMA approval document: Assessment Report EMA/78875/2015; EMEA/H/C/002780/0000, page:94 PDF 2992k",https://www.pharmapendium.com/browse/ema/Ospemifene/914a74ea04ee71d68d5550e58472bc00?reference=94,2014.0,OCCOC1=CC=C(C=C1)C(\C1=CC=CC=C1)=C(\CCCl)C1=CC=CC=C1
Pantoprazole Sodium,COC1=C(OC)C(=NC=C1)\C=S([O-])\C1=NC2=CC(OC(F)F)=CC=C2N1,Cholecystitis,Human,-2.380211241711606,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020987/S-007, page:44 PDF 1373k",https://www.pharmapendium.com/browse/fda/Pantoprazole Sodium/fc792609ea1639d725d409fa83f0f250?reference=44,2002.0,COC1=C(OC)C(=NC=C1)\C=S([O-])\C1=NC2=CC(OC(F)F)=CC=C2N1
Paroxetine Hydrochloride,FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC=C2OCOC2=C1,Cholecystitis,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 020031/S-007, S-009 Part 14, page:14 PDF 7890k",https://www.pharmapendium.com/browse/fda/Paroxetine Hydrochloride/1e96e023a0b79429147336e9cdd2032f?reference=14,1992.0,FC1=CC=C(C=C1)[CH]1CCNC[CH]1COC1=CC=C2OCOC2=C1
Pexidartinib Hydrochloride,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1,Cholecystitis,Human,-3.0,Repeated,Oral,"FDA approval package document: Approval Package 211810/S-000 Part 07, page:43 PDF 855k",https://www.pharmapendium.com/browse/fda/Pexidartinib Hydrochloride/b8014b9a95e2f8615062ebf1f04be996?reference=43,2019.0,FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1
Pinacidil,CC(C(C)(C)C)\N=C(/NC#N)NC1=CC=NC=C1,Cholecystitis,Human,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Approval Package 019456 Part 08, page:16 PDF 8290k",https://www.pharmapendium.com/browse/fda/Pinacidil/f75e16583c142370ef7bed18ba670f98?reference=16,1989.0,CC(C(C)(C)C)\N=C(/NC#N)NC1=CC=NC=C1
Pioglitazone Hydrochloride,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1,Cholecystitis,Human,-1.6532125137753437,Repeated,Oral,"EMA approval document: Scientific Discussion, page:20 PDF 297k",https://www.pharmapendium.com/browse/ema/Pioglitazone Hydrochloride/7e2fe86f1eb5292bd0df81d1b7d3a5de?reference=20,2003.0,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Posaconazole,CC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@@](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1,Cholecystitis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022003/S-000, page:125 PDF 8671k",https://www.pharmapendium.com/browse/fda/Posaconazole/f5037214d79cab10872dcc1e689683b6?reference=125,2005.0,CC[CH]([CH](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[CH]2CO[C](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1
Pralsetinib,CO[C@@]1(CC[C@@H](CC1)C1=NC(C)=CC(NC2=NNC(C)=C2)=N1)C(=O)N[C@@H](C)C1=CC=C(N=C1)N1C=C(F)C=N1,Cholecystitis,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 213721/S-000 Part 06, page:33 PDF 7982k",https://www.pharmapendium.com/browse/fda/Pralsetinib/26a0773d49143819947e790c5be9ae0d?reference=33,2020.0,CO[C]1(CC[CH](CC1)C1=NC(C)=CC(NC2=NNC(C)=C2)=N1)C(=O)N[CH](C)C1=CC=C(N=C1)N1C=C(F)C=N1
Pramipexole Dihydrochloride,CCCN[C@H]1CCC2=C(C1)SC(N)=N2,Cholecystitis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Label 022514/S-000, page:7 PDF 459k",https://www.pharmapendium.com/browse/fda/Pramipexole Dihydrochloride/670aee328b4355c20f586428ea2fcc64?reference=7,2010.0,CCCN[CH]1CCC2=C(C1)SC(N)=N2
Pregabalin,CC(C)C[C@H](CN)CC(O)=O,Cholecystitis,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021724/S-000 Part 02, page:76 PDF 6799k",https://www.pharmapendium.com/browse/fda/Pregabalin/4c007e1e38c4a693d58614dbb362044b?reference=76,2005.0,CC(C)C[CH](CN)CC(O)=O
Progesterone,[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=CC(=O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(C)=O,Cholecystitis,Human,-2.0,Repeated,Intravaginal,"FDA approval package document: Medical/Clinical Review 022057/S-000 Part 01, page:14 PDF 6452k",https://www.pharmapendium.com/browse/fda/Progesterone/55c1fff1ab48056a24f2d79e1d0a77d1?reference=14,2006.0,[H][C]1(CC[C]2([H])[C]3([H])CCC4=CC(=O)CC[C]4(C)[C]3([H])CC[C]12C)C(C)=O
Rabeprazole Sodium,COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3[N-]2)=NC=C1,Cholecystitis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020973, page:52 PDF 3861k",https://www.pharmapendium.com/browse/fda/Rabeprazole Sodium/cd5324d145f95f7fb7f9add29725eb72?reference=52,1999.0,COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3[N-]2)=NC=C1
Raloxifene Hydrochloride,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2,Cholecystitis,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022042/S-000 Part 06, page:29 PDF 7498k",https://www.pharmapendium.com/browse/fda/Raloxifene Hydrochloride/4ac438a6decad100cffa0a2a166f9107?reference=29,2007.0,OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
Regorafenib,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1,Cholecystitis,Human,-1.4471580313422192,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204369/S-000 Part 05, page:32 PDF 584k",https://www.pharmapendium.com/browse/fda/Regorafenib/21b662ab2b0a3f54a74c06b722a4a2d4?reference=32,2012.0,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
Rilpivirine Hydrochloride,CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1,Cholecystitis,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202022/S-000, page:68 PDF 1064k",https://www.pharmapendium.com/browse/fda/Rilpivirine Hydrochloride/9ced65a4af087352a74203f63a45eb54?reference=68,2011.0,CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1
Riluzole,NC1=NC2=CC=C(OC(F)(F)F)C=C2S1,Cholecystitis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 020599/S-003, page:17 PDF 7522k",https://www.pharmapendium.com/browse/fda/Riluzole/0d129eb827682356ebb219e7959abd71?reference=17,2003.0,NC1=NC2=CC=C(OC(F)(F)F)C=C2S1
Risedronate Sodium,OC(CC1=CC=CN=C1)(P(O)(O)=O)P(O)([O-])=O,Cholecystitis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020835, page:74 PDF 3171k",https://www.pharmapendium.com/browse/fda/Risedronate Sodium/4b91218ae65dbb3fdd344de6b389c5f0?reference=74,1999.0,OC(CC1=CC=CN=C1)(P(O)(O)=O)P(O)([O-])=O
Risperidone,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,Cholecystitis,Human,-1.2041199826559248,Repeated,Oral,"FDA approval package document: Approval Package 020588/S-004, page:20 PDF 5904k",https://www.pharmapendium.com/browse/fda/Risperidone/325911b581eedcab687690f8ef005a7b?reference=20,2002.0,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
Rivaroxaban,ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O,Cholecystitis,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022406/S-000 Part 16, page:4 PDF 394k",https://www.pharmapendium.com/browse/fda/Rivaroxaban/ba755011cb37ec9d494dd6be76a6ea40?reference=4,2009.0,ClC1=CC=C(S1)C(=O)NC[CH]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
Rofecoxib,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1,Cholecystitis,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Approval Package 021042/S-026; 021052/S-019 Part 01, page:30 PDF 7078k",https://www.pharmapendium.com/browse/fda/Rofecoxib/df9860bde38cd670ee5b5cf92d1a0b45?reference=30,2003.0,CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1
Ropinirole Hydrochloride,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2,Cholecystitis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020658/S-000 Part 03, page:27 PDF 2663k",https://www.pharmapendium.com/browse/fda/Ropinirole Hydrochloride/6d213090e5326dc5ec9947a37a6cece7?reference=27,1995.0,CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2
Rotigotine,CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1,Cholecystitis,Human,-1.255272505103306,Repeated,Skin,"FDA approval package document: Medical/Clinical Review 021829/S-000 Part 04, page:8 PDF 10263k",https://www.pharmapendium.com/browse/fda/Rotigotine/30b1f8e9e21642f5d7dbd88aed8e5913?reference=8,2006.0,CCCN(CCC1=CC=CS1)[CH]1CCC2=C(O)C=CC=C2C1
Rufinamide,NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1,Cholecystitis,Human,-3.2041199826559246,Repeated,Oral,"EMA approval document: Scientific Discussion, page:46 PDF 700k",https://www.pharmapendium.com/browse/ema/Rufinamide/3770c534da4fbf3b2750b0d726cd215b?reference=46,2007.0,NC(=O)C1=CN(CC2=C(F)C=CC=C2F)N=N1
Saxagliptin Hydrochloride,[H][C@]12C[C@]3([H])C[C@](O)(C1)C[C@](C2)(C3)[C@H](N)C(=O)N1[C@@H](C[C@]2([H])C[C@]12[H])C#N,Cholecystitis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022350/S-000 Part 02, page:29 PDF 7700k",https://www.pharmapendium.com/browse/fda/Saxagliptin Hydrochloride/f655ce6372bb37a28b774eb72e961cf9?reference=29,2009.0,[H][C]12C[C]3([H])C[C](O)(C1)C[C](C2)(C3)[CH](N)C(=O)N1[CH](C[C]2([H])C[C]12[H])C#N
Sertraline Hydrochloride,CN[C@H]1CC[C@@H](C2=CC=C(Cl)C(Cl)=C2)C2=C1C=CC=C2,Cholecystitis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 019839/S-026 Part 01, page:31 PDF 1532k",https://www.pharmapendium.com/browse/fda/Sertraline Hydrochloride/d4d6062847ef11629a4dacf555728145?reference=31,1998.0,CN[CH]1CC[CH](C2=CC=C(Cl)C(Cl)=C2)C2=C1C=CC=C2
Sibutramine Hydrochloride,CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1,Cholecystitis,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Label 020632/S-026, page:25 PDF 449k",https://www.pharmapendium.com/browse/fda/Sibutramine Hydrochloride/b4146d51261d5cb8abba7bdc27f31629?reference=25,2006.0,CC(C)CC(N(C)C)C1(CCC1)C1=CC=C(Cl)C=C1
Sodium Oxybate,OCCCC([O-])=O,Cholecystitis,Human,-3.9542425094393248,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021196/S-000 Part 10, page:2 PDF 1551k",https://www.pharmapendium.com/browse/fda/Sodium Oxybate/8284148121cddd830616b0e2c1af886e?reference=2,2001.0,OCCCC([O-])=O
Sunitinib,CCN(CC)CCNC(=O)C1=C(C)NC(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C,Cholecystitis,Human,-1.8750612633917,Repeated,Oral,"EMA approval document: ANNEX I, page:81 PDF 705k",https://www.pharmapendium.com/browse/ema/Sunitinib/95d35eea3df7c71029f241d18fa5927a?reference=81,2021.0,CCN(CC)CCNC(=O)C1=C(C)NC(/C=C2\C(=O)NC3=CC=C(F)C=C23)=C1C
Suprofen,CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1,Cholecystitis,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 018217/S-011, S-009 Part 03, page:2 PDF 3520k",https://www.pharmapendium.com/browse/fda/Suprofen/06b3cbea2f2ca2086fb74640069d058f?reference=2,1985.0,CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1
Tacrine Hydrochloride,NC1=C2C=CC=CC2=NC2=C1CCCC2,Cholecystitis,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 020070/S-001, S-003, S-004, S-006 Part 01, page:15 PDF 10320k",https://www.pharmapendium.com/browse/fda/Tacrine Hydrochloride/bccf76edc873f241b1898b3994cb3b19?reference=15,1993.0,NC1=C2C=CC=CC2=NC2=C1CCCC2
Tadalafil,[H][C@]12CC3=C(NC4=C3C=CC=C4)[C@H](N1C(=O)CN(C)C2=O)C1=CC=C2OCOC2=C1,Cholecystitis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Approval Package 021368/S-020 Part 06, page:5 PDF 297k",https://www.pharmapendium.com/browse/fda/Tadalafil/78ff04f57d523cfcda4a721862a9ff8d?reference=5,2011.0,[H][C]12CC3=C(NC4=C3C=CC=C4)[CH](N1C(=O)CN(C)C2=O)C1=CC=C2OCOC2=C1
Tedizolid Phosphate,CN1N=NC(=N1)C1=CC=C(C=N1)C1=C(F)C=C(C=C1)N1C[C@H](COP(O)(O)=O)OC1=O,Cholecystitis,Human,-2.3010299956639813,Repeated,Unreported,"FDA approval package document: Medical/Clinical Review 205435/S-000 Part 06, page:28 PDF 12856k",https://www.pharmapendium.com/browse/fda/Tedizolid Phosphate/a1c0cb6144dbc2946f883f0e271ecdda?reference=28,2014.0,CN1N=NC(=N1)C1=CC=C(C=N1)C1=C(F)C=C(C=C1)N1C[CH](COP(O)(O)=O)OC1=O
Telaprevir,[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1,Cholecystitis,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 201917/S-000 Part 03, page:33 PDF 888k",https://www.pharmapendium.com/browse/fda/Telaprevir/38a977d1e6ed2d08496cec1e1881f7b1?reference=33,2011.0,[H][C]12CCC[C]1([H])[CH](N(C2)C(=O)[CH](NC(=O)[CH](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[CH](CCC)C(=O)C(=O)NC1CC1
Tenapanor Hydrochloride,CN1C[C@@H](C2=CC(=CC=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C2=CC=CC(=C2)[C@@H]2CN(C)CC3=C2C=C(Cl)C=C3Cl)C2=C(C1)C(Cl)=CC(Cl)=C2,Cholecystitis,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 211801/S-000 Part 09, page:3 PDF 516k",https://www.pharmapendium.com/browse/fda/Tenapanor Hydrochloride/fa9725aaf25c7ebe57f8a6eb43b955ef?reference=3,2019.0,CN1C[CH](C2=CC(=CC=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C2=CC=CC(=C2)[CH]2CN(C)CC3=C2C=C(Cl)C=C3Cl)C2=C(C1)C(Cl)=CC(Cl)=C2
Terazosin Hydrochloride,COC1=CC2=NC(=NC(N)=C2C=C1OC)N1CCN(CC1)C(=O)C1CCCO1,Cholecystitis,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Approval Package 019057/S-006, S-002, S-001, S-008, S-003, S-004, S-009, S-011; 020347/S-002 Part 10, page:15 PDF 6604k",https://www.pharmapendium.com/browse/fda/Terazosin Hydrochloride/cb3663ddc26c6c255b6db4eebb0edf2e?reference=15,1988.0,COC1=CC2=NC(=NC(N)=C2C=C1OC)N1CCN(CC1)C(=O)C1CCCO1
Teriflunomide,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F,Cholecystitis,Human,-1.146128035678238,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202992/S-000 Part 12, page:57 PDF 11938k",https://www.pharmapendium.com/browse/fda/Teriflunomide/9711c01cf59f491dbbc62266f7c8962f?reference=57,2012.0,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Tiagabine Hydrochloride,CC1=C(SC=C1)/C(=C/CCN1CCC[C@H](C1)C(O)=O)/C1=C(C)C=CS1,Cholecystitis,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020646/S-000 Part 04, page:44 PDF 2459k",https://www.pharmapendium.com/browse/fda/Tiagabine Hydrochloride/60d6596af59b73495b7ace76bb1bd99c?reference=44,1997.0,CC1=C(SC=C1)/C(=C/CCN1CCC[CH](C1)C(O)=O)/C1=C(C)C=CS1
Ticagrelor,CCCSC1=NC(N[C@@H]2C[C@H]2C2=CC=C(F)C(F)=C2)=C2N=NN([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)C2=N1,Cholecystitis,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 022433/S-015 Part 09, page:7 PDF 1419k",https://www.pharmapendium.com/browse/fda/Ticagrelor/c6af8f154a99fed015f44c884764f907?reference=7,2015.0,CCCSC1=NC(N[CH]2C[CH]2C2=CC=C(F)C(F)=C2)=C2N=NN([CH]3C[CH](OCCO)[CH](O)[CH]3O)C2=N1
Tiotropium Bromide,[H][C@]12O[C@@]1([H])[C@]1([H])C[C@H](C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1,Cholecystitis,Human,-1.255272505103306,Repeated,Inhalation,"FDA approval package document: Medical/Clinical Review 021936/S-000 Part 02, page:88 PDF 15819k",https://www.pharmapendium.com/browse/fda/Tiotropium Bromide/8d1ee12dc3aff2bfbea47dd903974707?reference=88,2008.0,[H][C]12O[C]1([H])[C]1([H])C[CH](C[C]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
Tipranavir,CCC[C@@]1(CCC2=CC=CC=C2)CC(O)=C([C@H](CC)C2=CC=CC(NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)=C2)C(=O)O1,Cholecystitis,Human,-2.8750612633917,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021814/S-000 Part 01, page:91 PDF 5219k",https://www.pharmapendium.com/browse/fda/Tipranavir/42a8e8d5064569f01f0c499d1ef01d7e?reference=91,2005.0,CCC[C]1(CCC2=CC=CC=C2)CC(O)=C([CH](CC)C2=CC=CC(NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)=C2)C(=O)O1
Tolcapone,CC1=CC=C(C=C1)C(=O)C1=CC(O)=C(O)C(=C1)N(=O)=O,Cholecystitis,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020697/S-000 Part 02, page:21 PDF 1427k",https://www.pharmapendium.com/browse/fda/Tolcapone/2e0fd4e2cdd94c7d4fe7c8a03f89c449?reference=21,1996.0,CC1=CC=C(C=C1)C(=O)C1=CC(O)=C(O)C(=C1)N(=O)=O
Topiramate,[H][C@@]12OC(C)(C)O[C@]1(COS(N)(=O)=O)OC[C@H]1OC(C)(C)O[C@@H]21,Cholecystitis,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 205122/S-000 Part 03, page:41 PDF 1429k",https://www.pharmapendium.com/browse/fda/Topiramate/936967b60b3ceccff076ce2155304946?reference=41,2014.0,[H][C]12OC(C)(C)O[C]1(COS(N)(=O)=O)OC[CH]1OC(C)(C)O[CH]21
Tramadol Hydrochloride,COC1=CC(=CC=C1)[C@]1(O)CCCC[C@H]1CN(C)C,Cholecystitis,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021692/S-000 Part 01, page:40 PDF 4501k",https://www.pharmapendium.com/browse/fda/Tramadol Hydrochloride/68c567910e2ca0778f03f0ab4a335dde?reference=40,2005.0,COC1=CC(=CC=C1)[C]1(O)CCCC[CH]1CN(C)C
Trandolapril,[H][C@]12CCCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC,Cholecystitis,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Approval Package 020528/S-001 Part 02, page:18 PDF 1012k",https://www.pharmapendium.com/browse/fda/Trandolapril/281895f55f444bcb4024286951c134cb?reference=18,1996.0,[H][C]12CCCC[C]1([H])N([CH](C2)C(O)=O)C(=O)[CH](C)N[CH](CCC1=CC=CC=C1)C(=O)OCC
Tucatinib,CC1=CC(NC2=C3C=C(NC4=NC(C)(C)CO4)C=CC3=NC=N2)=CC=C1OC1=CC2=NC=NN2C=C1,Cholecystitis,Human,-2.4771212547196626,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/78409/2021; EMEA/H/C/005263/0000, page:125 PDF 7669k",https://www.pharmapendium.com/browse/ema/Tucatinib/9853a892aaf187403450ff694ca2cbcd?reference=125,2020.0,CC1=CC(NC2=C3C=C(NC4=NC(C)(C)CO4)C=CC3=NC=N2)=CC=C1OC1=CC2=NC=NN2C=C1
Umeclidinium Bromide,OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2,Cholecystitis,Human,-0.6989700043360189,Repeated,Inhalation,"FDA approval package document: Medical/Clinical Review 205382/S-000 Part 02, page:101 PDF 19535k",https://www.pharmapendium.com/browse/fda/Umeclidinium Bromide/01970e63ea746b629343cb76ead136db?reference=101,2013.0,OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2
Valdecoxib,CC1=C(C2=CC=C(C=C2)S(N)(=O)=O)C(=NO1)C1=CC=CC=C1,Cholecystitis,Human,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021341/S-000 Part 03, page:74 PDF 3669k",https://www.pharmapendium.com/browse/fda/Valdecoxib/393cae7dcde505c5b787ef005d70b3c6?reference=74,2001.0,CC1=C(C2=CC=C(C=C2)S(N)(=O)=O)C(=NO1)C1=CC=CC=C1
Venetoclax,CC1(C)CCC(CN2CCN(CC2)C2=CC(OC3=CN=C4NC=CC4=C3)=C(C=C2)C(=O)NS(=O)(=O)C2=CC=C(NCC3CCOCC3)C(=C2)N(=O)=O)=C(C1)C1=CC=C(Cl)C=C1,Cholecystitis,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 208573/S-020; 208573/S-021 Part 13, page:19 PDF 9744k",https://www.pharmapendium.com/browse/fda/Venetoclax/3488d6fcf4b5e5bdbfa4f42ba6016f00?reference=19,2020.0,CC1(C)CCC(CN2CCN(CC2)C2=CC(OC3=CN=C4NC=CC4=C3)=C(C=C2)C(=O)NS(=O)(=O)C2=CC=C(NCC3CCOCC3)C(=C2)N(=O)=O)=C(C1)C1=CC=C(Cl)C=C1
Venlafaxine Hydrochloride,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1,Cholecystitis,Human,-2.574031267727719,Repeated,Oral,"FDA approval package document: Approval Package 076565/S-000 Part 01, page:12 PDF 430k",https://www.pharmapendium.com/browse/fda/Venlafaxine Hydrochloride/5cd234a6c0473f68efdb6f0cc83b8642?reference=12,2010.0,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
Vigabatrin,NC(CCC(O)=O)C=C,Cholecystitis,Human,-3.7781512503836434,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020427/S-000 Part 02, page:15 PDF 6981k",https://www.pharmapendium.com/browse/fda/Vigabatrin/8df119ca2ebfd8c7300d5bc513a92a8d?reference=15,2009.0,NC(CCC(O)=O)C=C
Voriconazole,C[C@@H](C1=C(F)C=NC=N1)[C@](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F,Cholecystitis,Human,-1.0791812460476249,Repeated,Intravenous,"FDA approval package document: Approval Package 021266/S-009, 021267/S-009, 021630/S-003 Part 03, page:15 PDF 309k",https://www.pharmapendium.com/browse/fda/Voriconazole/6bf2dd491c6903c4f6aa215436a65f75?reference=15,2004.0,C[CH](C1=C(F)C=NC=N1)[C](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F
Vorinostat,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1,Cholecystitis,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021991/S-000 Part 03, page:25 PDF 5109k",https://www.pharmapendium.com/browse/fda/Vorinostat/615f4b6c981004a1de417634f31050a6?reference=25,2006.0,ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
Vortioxetine Hydrobromide,CC1=CC(C)=C(SC2=CC=CC=C2N2CCNCC2)C=C1,Cholecystitis,Human,-1.3010299956639813,Repeated,Oral,"EMA approval document: Assessment Report EMA/699150/2013; EMEA/H/C/002717, page:137 PDF 3890k",https://www.pharmapendium.com/browse/ema/Vortioxetine Hydrobromide/8cd22d75881b8772fc367ac141642ea5?reference=137,2013.0,CC1=CC(C)=C(SC2=CC=CC=C2N2CCNCC2)C=C1
Zalcitabine,NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](CO)O1,Cholecystitis,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Approval Package 020199 Part 11, page:8 PDF 6994k",https://www.pharmapendium.com/browse/fda/Zalcitabine/a23abfaff31eeb2231f8321ed61f5a7c?reference=8,1992.0,NC1=NC(=O)N(C=C1)[CH]1CC[CH](CO)O1
Zileuton,CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1,Cholecystitis,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Medical Officer Review 020471 Part 02, page:65 PDF 2450k",https://www.pharmapendium.com/browse/fda/Zileuton/6a2e76573bc6d0dcbea01f19666c1454?reference=65,1995.0,CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
Zonisamide,NS(=O)(=O)CC1=NOC2=CC=CC=C12,Cholecystitis,Human,-2.845098040014257,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020789/S-000 Part 03, page:25 PDF 1355k",https://www.pharmapendium.com/browse/fda/Zonisamide/ac1b02807a7e974177a672792ccc3fbe?reference=25,1997.0,NS(=O)(=O)CC1=NOC2=CC=CC=C12
